133 research outputs found
‐125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer's disease
No full textSporadic Alzheimer's disease (AD) is the most prevalent form of dementia, but no clear disease-initiating mechanism is known. Ab deposits and neuronal tangles composed of hyperphosphorylated tau are characteristic for AD. Here, we analyze the contribution of microRNA-125b (miR-125b), which is elevated in AD. In primary neurons, overexpression of miR-125b causes tau hyperphosphorylation and an upregulation of p35, cdk5, and p44/42-MAPK signaling. In parallel, the phosphatases DUSP6 and PPP1CA and the anti-apoptotic factor Bcl-W are downregulated as direct targets of miR-125b. Knockdown of these phosphatases induces tau hyperphosphorylation, and overexpression of PPP1CA and Bcl-W prevents miR-125b-induced tau phosphorylation, suggesting that they mediate the effects of miR-125b on tau. Conversely, suppression of miR-125b in neurons by tough decoys reduces tau phosphorylation and kinase expression/activity. Injecting miR-125b into the hippocampus of mice impairs associative learning and is accompanied by downregulation of Bcl-W, DUSP6, and PPP1CA, resulting in increased tau phosphorylation in vivo. Importantly, DUSP6 and PPP1CA are also reduced in AD brains. These data implicate miR-125b in the pathogenesis of AD by promoting pathological tau phosphorylation
Chronic T cell proliferation in brains after stroke could interfere with the efficacy of immunotherapies
No full textNeuroinflammation is an emerging focus of translational stroke research. Preclinical studies have demonstrated a critical role for brain-invading lymphocytes in post-stroke pathophysiology. Reducing cerebral lymphocyte invasion by anti-CD49d antibodies consistently improves outcome in the acute phase after experimental stroke models. However, clinical trials testing this approach failed to show efficacy in stroke patients for the chronic outcome 3 mo after stroke. Here, we identify a potential mechanistic reason for this phenomenon by detecting chronic T cell accumulation—evading the systemic therapy—in the post-ischemic brain. We observed a persistent accumulation of T cells in mice and human autopsy samples for more than 1 mo after stroke. Cerebral T cell accumulation in the post-ischemic brain was driven by increased local T cell proliferation rather than by T cell invasion. This observation urges re-evaluation of current immunotherapeutic approaches, which target circulating lymphocytes for promoting recovery after stroke
DNA-Vakzinierung mit Idiotyp Zytokin Fusionskonstrukten gegen Lymphome im Mausmodell
No full textDie vorliegende Arbeit beschäftigt sich mit neuen Ansätzen zur Immuntherapie von B-Zell-Lymphomen. Als Mausmodell wurden das Lymphom A20 und der eher leukämisch wachsende BCL1-Tumor verwendet. Alle Zellen eines B-Zell-Lymphoms produzieren einen identischen Antikörper, den sogenannten Idiotyp, der als tumorspezifisches Antigen benutzt werden kann: Die antigenbindenden variablen Regionen von schwerer und leichter Kette sind für die Tumorzellen jedes Patienten spezifisch. Die variablen Regionen lassen sich mit einem flexiblen Linker-Peptid zu single-chain Fragmenten (scFv) fusionieren. Die Antigenbindung und die Struktur als Tumorantigen bleiben dabei erhalten. Die BCL1-Sequenz war bereits bekannt, sie ließ sich mit Hilfe familienspezischer Primer mit PCR amplifizieren und klonieren. Bei der stark hypermutierten Sequenz des A20-Idiotyps versagte das Standardverfahren der Konsensus-Primer, erst eine 5'-RACE-PCR war erfolgreich.
Der optimale Effektormechanismus (humoral, CD4 oder CD8 vermittelt) zur Immuntherapie von Lymphomen ist nicht bekannt. Bei DNA-Vakzinen lässt sich die Immunantwort besonders effektiv modulieren. Hier wurde ein System entwickelt, um rasch die Wirksamkeit verschiedener Kombinationen in vivo untersuchen zu können: Der scFv-Idiotyp wurde mit einem Zytokin (IL1beta, IL4, IL12, GM-CSF oder Flt3 ligand) und/oder einem Adjuvans (Tetanus Toxin Fragment C oder HBsAg) gekoppelt. In vitro wurde die Expression, die Faltung des scFv und die biologische Aktivität bestätigt. Neben der spezifischen Zytokinwirkung stabilisieren die Fusionspartner die scFv-Proteine deutlich.
Zunächst wurde mit dem Modellantigen HBsAg die Immunisierungstechnik optimiert: Intradermale Plasmid-Injektion in die Ohr Pinna ergab konsistent hohe Antikörper-Titer. Bereits ohne in vitro-Restimulation konnte eine starke zelluläre Antwort nachgewiesen werden. Weiterhin wurde für die beiden Tumormodelle A20 und BCL1 die Wachstumskinetik invivo bestimmt und ein Pilotversuch (32 Tiere) mit drei ausgewählten Konstrukten durchgeführt: Von sechs splenektomierten Mäusen zeigte nur eine nach zwei Immunisierungen eine spezifische zelluläre Antwort gegen A20. In keiner Versuchsgruppe zeigte sich eine signifikante Lebensverlängerung nach Lymphomchallenge.
Zusammenfassend ist erstmalig ein System entwickelt worden, das es auf einfache Weise ermöglicht, die Wirksamkeit von verschiedenen Zytokinen und Adjuvantien zur Idiotyp-Vakzinierung zu untersuchen. Dieses System bietet viel Raum für Optimierungen
Distinct Roles of NR2A and NR2B Cytoplasmic Tails in Long-Term
No full textNMDA receptors (NMDARs) are critical mediators of activity-dependent synaptic plasticity, but the differential roles of NR2A- versus NR2B-containing NMDARs have been controversial. Here, we investigate the roles of NR2A and NR2B in long-term potentiation (LTP) in organotypic hippocampal slice cultures using RNA interference (RNAi) and overexpression, to complement pharmacological approaches. In young slices, when NR2B is the predominant subunit expressed, LTP is blocked by the NR2B-selective antagonist Ro25-6981 [R-(R,S)-{alpha}-(4-hydroxyphenyl)-β-methyl-4-(phenylmethyl)-1-piperidine propranol]. As slices mature and NR2A expression rises, activation of NR2B receptors became no longer necessary for LTP induction. LTP was blocked, however, by RNAi knockdown of NR2B, and this was rescued by coexpression of an RNAi-resistant NR2B (NR2B*) cDNA. Interestingly, a chimeric NR2B subunit in which the C-terminal cytoplasmic tail was replaced by that of NR2A failed to rescue LTP, whereas the reverse chimera, NR2A channel with NR2B tail, was able to restore LTP. Thus, expression of NR2B with its intact cytoplasmic tail is required for LTP induction, at an age when channel activity of NR2B–NMDARs is not required for LTP. Overexpression of wild-type NR2A failed to rescue LTP in neurons transfected with the NR2B–RNAi construct, despite restoring NMDA–EPSC amplitude to a similar level as NR2B*. Surprisingly, an NR2A construct lacking its entire C-terminal cytoplasmic tail regained its ability to restore LTP. Together, these data suggest that the NR2B subunit plays a critical role for LTP, presumably by recruiting relevant molecules important for LTP via its cytoplasmic tail. In contrast, NR2A is not essential for LTP, and its cytoplasmic tail seems to carry inhibitory factors for LTP
RNA-Dependent Intergenerational Inheritance of Enhanced Synaptic Plasticity after Environmental Enrichment
No full textSummary: Physical exercise in combination with cognitive training is known to enhance synaptic plasticity, learning, and memory and lower the risk for various complex diseases including Alzheimer’s disease. Here, we show that exposure of adult male mice to an environmental enrichment paradigm leads to enhancement of synaptic plasticity and cognition also in the next generation. We show that this effect is mediated through sperm RNA and especially miRs 212/132. In conclusion, our study reports intergenerational inheritance of an acquired cognitive benefit and points to specific miRs as candidates mechanistically involved in this type of transmission. : Environmental enrichment (EE), a combination of physical and mental exercise, has been shown to increase cognitive abilities in mice and in humans. Benito et al. find that offspring of male mice subjected to EE also show this increase. This effect is dependent on sperm RNA and involves microRNA212/132. Keywords: epigenetics, brain, microRNA, memory, intergenerational, transgenerational, exercise, environmental enrichment, cognitio
Correction to: Gel‐like inclusions of C‐terminal fragments of TDP‐43 sequester stalled proteasomes in neurons (EMBO reports, (2022), 23, 6, (e53890), 10.15252/embr.202153890)
No full text(Figure presented.)</p
Good guy or bad guy: the opposing roles of microRNA 125b in cancer
No full textMicroRNAs (miRNAs) are a class of non-coding RNAs that post-transcriptionally silence target mRNAs. Dysregulation of miRNAs is a frequent event in several diseases, including cancer. One miRNA that has gained special interest in the field of cancer research is miRNA-125b (miR-125b). MiR-125b is a ubiquitously expressed miRNA that is aberrantly expressed in a great variety of tumors. In some tumor types, e. g. colon cancer and hematopoietic tumors, miR-125b is upregulated and displays oncogenic potential, as it induces cell growth and proliferation, while blocking the apoptotic machinery. In contrast, in other tumor entities, e. g. mammary tumors and hepatocellular carcinoma, miR-125b is heavily downregulated. This downregulation is accompanied by de-repression of cellular proliferation and anti-apoptotic programs, contributing to malignant transformation. The reasons for these opposing roles are poorly understood. We summarize the current knowledge of miR-125b and its relevant targets in different tumor types and offer several hypotheses for the opposing roles of miR-125b: miR-125b targets multiple mRNAs, which have diverse functions in individual tissues. These target mRNAs are tissue and tumor specifically expressed, suggesting that misregulation by miR-125b depends on the levels of target gene expression. Moreover, we provide several examples that miR-125b upregulation dictates oncogenic characteristics, while downregulation of miR-125b corresponds to the loss of tumor suppressive functions. Thus, in different tumor entities increased or decreased miR-125b expression may contribute to carcinogenesis
Dissecting the contribution of dipeptide repeats to the toxicity in C9orf72 iPSC-derived neurons from ALS/FTD patients
No full textA large (GGGGCC) repeat expansion in C9ORF72 gene is the commonest genetic cause of amyotrophic lateral sclerosis (ALS). It causes both loss- and gain-of-function, but the relative contribution of the different mechanisms to the development of ALS remains uncertain. One of the pathomechanisms is the production of dipeptide repeat proteins (PR, PA, GR, GP and GA) via repeat-associated non-ATG translation (DPRs). Animal and cellular models have suggested that the arginine-rich DPRs are toxic, but staining in fixed brains of C9orf72 patients show that the same DPRs are not very abundant compared to GA, GP and PA. Moreover, the DPR-related phenotypes exhibited in in vitro models are not always verified in C9orf72 patients. For these reasons I developed a doxycycline-inducible lentiviral system to regulate DPR expression in induced pluripotent stem cell (iPSC)-derived motor neuron (MN) cultures. The effects of GA and PR expression in CRISPR/Cas9 corrected C9orf72 iPSC-derived MNs were compared to the phenotypes of C9orf72 mutant lines. Both DPRs were partially accountable for altered ER and mitochondrial calcium homeostasis, and stress granule formation. Moreover, PR expression may reduce maximal mitochondrial respiration, while GA induced lysosomal activation. The activation of chaperone-mediated autophagy cleared CRISPR/Cas9 corrected iPSC-derived MNs from GA and PR, but it did not rescue C9orf72 mutant lines. Moreover, I studied the effects of a peptide designed to reduce RNA foci, and I showed that it may improve mitochondrial respiration in C9orf72 mutant iPSC-derived MNs
An amyloid-like cascade hypothesis for C9orf72 ALS/FTD
No full textExpansion of a GGGGCC repeat in C9orf72 causes amyotrophic lateral sclerosis, frontotemporal dementia, or a combination of both. Bidirectional repeat transcripts sequester RNA-binding proteins into nuclear RNA foci. The repeat is translated into dipeptide repeat (DPR) proteins that are crucial for repeat-induced toxicity. DPRs inhibit the proteasome and sequester other proteins. These changes are accompanied by widespread brain atrophy and subclinical cognitive impairment before disease onset. Both repeat RNA and DPRs impair nucleocytoplasmic transport and promote TDP-43 mislocalization and aggregation. Thus, repeat RNA and DPRs may gradually trigger TDP-43 pathology and subsequent region-specific neurodegeneration in a cascade similar to amyloid-β peptide in Alzheimer's disease. The key components of the C9orf72 cascade are promising therapeutic targets in different disease stages
- …
